CA-CROWN-BIOSCIENCE
Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005031/en/
Mr. Gu joins CrownBio from WuXi Nextcode, a global leader in genomic data analysis, where he was general manager for the China business, as well as chief digital officer. At WuXi Nextcode, John spearheaded a block-chain enabled secure mobile health data bank integrating genomic, clinical and behavioral data for precision healthcare. He also led the effort to apply big data and AI technologies to improve medical genomic interpretation accuracy and efficiency and to improve customer experience via digital technologies.
“I am thrilled to welcome John to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “John brings a wealth of experience in global business and operational transformation, and his deep expertise in the growth of technology platforms will be instrumental in helping CrownBio’s global operations evolve and excel, and at the same time develop our innovative digital and in silico preclinical solutions.”
Prior to WuXi Nextcode, Mr. Gu held successive senior technology and operations roles across digital and technology companies, where he successfully led multiple large-scale global IT transformation projects. This includes Alcatel-Lucent, where John led the IT integration and digital transformation across operations in over 140 countries.
“I am delighted to join CrownBio at this point in time,” said John Gu. “Life science is experiencing exponential growth due to recent developments in science and technologies across multiple disciplines. Through enhanced operational excellence, innovation, and digital technologies, we are well poised to continue to deliver value to our customers.”
Mr. Gu holds an MBA from the University of Chicago, an MS in Computer Science from Loyola University of Chicago, and a double-major BS in Computer Science and Electrical Engineering from Shanghai Jiao Tong University.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.crownbio.com
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Publishes 2025 ESG Progress Report: Advancing Integrity, Innovation, and Impact23.10.2025 22:05:00 CEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2025 Environmental, Social, and Governance (ESG) Progress Report, covering its progress in 2024 and underscoring the company’s commitment to responsible business, data integrity, and inclusive growth across its global operations. “As a leading consumer intelligence company, our responsibility extends far beyond the industries we serve,” said Jim Peck, Executive Chairman and CEO of NIQ. “This year’s ESG Progress Report demonstrates how we are embedding sustainable and inclusive principles into our business, driving value for our clients, investors, associates, and communities.” Key progress areas from 2024Strengthened ESG governance: NIQ formalized its internal ESG governance framework and initiated a Double Materiality Assessment, aligning with the latest global standards and regulations. Advanced data integrity and security: The company advanced its use of AI and machine learning to ensure data quality, priva
Andersen Consulting udvider sine digitale transformationskompetencer med MOYO23.10.2025 19:47:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sine transformationskompetencer inden for teknologi og forretning via en samarbejdsaftale med MOYO, der er et digitalt konsulenthus, som leverer integrerede løsninger inden for strategi, data, teknologi, programmering og talentudvikling. MOYO, der blev grundlagt i 2007 af administrerende direktør Pierre le Roux, kombinerer tjenester inden for rådgivning, teknologi og humankapital-tjenester for at hjælpe en bred kundebase – fra startups til store virksomheder inden for finansielle tjenester, minedrift og detailhandel – med at implementere skalerbare systemer, optimere processer og levere skræddersyede løsninger, der udnytter nye muligheder i den digitale økonomi. "Hos MOYO mener vi, at digital transformation kun lykkes, når løsninger skabes med dyb empati og en klar forståelse for menneskene bag virksomheden," sagde Pierre. "Vores samarbejde med Andersen Consulting afspejler det samme engagement i at skabe meningsfulde, langsigtede forandring
Berry Consultants Releases FACTS 8 Clinical Trial Simulator23.10.2025 19:00:00 CEST | Press release
FACTS 8 introduces support for Ordinal endpoints and a new “Quick Start” feature Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/ FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements: Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis. A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provide
Saudi Arabia to Host 26th UN Tourism General Assembly in November Marking Agency’s 50th Year23.10.2025 16:58:00 CEST | Press release
The Kingdom of Saudi Arabia will host the 26th session of the UN Tourism General Assembly from November 7 to 11. The landmark session will focus on “AI-Powered Tourism: Redefining the Future” and also commemorate five decades of cooperation under the United Nations’ specialized agency for tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022579574/en/ Riyadh Nighttime View Represented by its Ministry of Tourism, Saudi Arabia will welcome more than 160 member states, international organizations, and global industry players to engage in dialogue aimed at securing a brighter, more sustainable future for the industry and shaping the next 50 years of global tourism. Saudi Arabia’s Minister of Tourism, H.E. Ahmed Al Khateeb, invited the world to Riyadh to take part in a momentous milestone for global tourism diplomacy: “We look forward to hosting the world’s leading organization for tourism in a session that will redefine
Macrobond and FactSet Collaborate to Deliver Direct Access to Global Equity Data on a Single Integrated Research Platform23.10.2025 15:49:00 CEST | Press release
This integration brings FactSet’s market-leading fundamentals, estimates, and ETF data directly into Macrobond’s intuitive platform. Macrobond, the leading provider of global economic and financial data and analytics, today announced a strategic integration with FactSet, a global digital platform and enterprise solutions provider. This collaboration provides Macrobond users with direct access to FactSet’s extensive equity and ETF datasets—including fundamentals, consensus estimates, market aggregates, and equity prices and returns —within the Macrobond platform. By combining Macrobond’s top-down macroeconomic insights with FactSet’s bottom-up company analysis, this collaboration delivers a uniquely complementary dataset that empowers clients to seamlessly integrate global economic trends with detailed security-level intelligence. This integration creates a seamless environment for economists, strategists, and analysts to analyze equity data with the efficiency and precision that define
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom